Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs Feb 24, 2025 08:13PM
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 Mar 14, 2024 07:00AM
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference Mar 5, 2024 07:00AM
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 Feb 20, 2024 07:00AM
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Feb 14, 2024 07:00AM
View Older Stories

Feb 14, 2024 07:00AM Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
Feb 7, 2024 07:00AM Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
Jan 8, 2024 09:00AM Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
Jan 3, 2024 07:30AM Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 7, 2023 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Nov 2, 2023 04:41PM Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
Oct 31, 2023 08:00AM Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
Oct 26, 2023 08:00AM Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
Oct 19, 2023 08:00AM H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
Oct 16, 2023 07:02AM Summit Therapeutics (SMMT) Appoints Leader Manmeet S. Soni as COO
Oct 16, 2023 07:00AM Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
Aug 9, 2023 07:00AM Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
Aug 2, 2023 08:00AM Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
Jun 4, 2023 08:00AM Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
Jun 1, 2023 07:30AM Ivonescimab Updated Data to be Featured at ASCO 2023
May 11, 2023 07:30AM Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023
May 9, 2023 07:30AM Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
Mar 9, 2023 07:30AM Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Mar 3, 2023 08:00AM Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
Feb 23, 2023 08:00AM Summit Therapeutics’ Rights Offering Nearing Expiration Date
Jan 30, 2023 08:00AM Summit Therapeutics (SMMT) Announces Timing for Rights Offering for Up to $500M
Jan 30, 2023 08:00AM Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
Jan 20, 2023 08:00AM Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
Jan 5, 2023 07:00AM Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6, 2022 08:01AM Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody,
Dec 6, 2022 07:31AM Summit Therapeutics (SMMT) Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Dec 6, 2022 07:30AM Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Nov 17, 2022 04:16PM Summit Therapeutics (SMMT) Appoints Alessandra Cesano to its Board
Nov 17, 2022 04:15PM Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Nov 9, 2022 08:30AM Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
Oct 20, 2022 05:15PM Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Oct 13, 2022 08:00AM Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Oct 3, 2022 04:37PM Summit Therapeutics (SMMT) Appoints Robert Booth to its Board
Oct 3, 2022 04:36PM Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors
Aug 11, 2022 08:00AM Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Jul 26, 2022 04:16PM Summit Therapeutics (SMMT) Appoints Maky Zanganeh as Co-CEO & President
Jul 26, 2022 04:15PM Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
Jul 14, 2022 08:33AM Summit Therapeutics (SMMT) Provides Update on Ridinilazole, Pathway Would Involve at Least One Additional Clinical Trial
Jul 14, 2022 08:30AM Summit Therapeutics Provides Update on Ridinilazole
Jun 22, 2022 04:30PM Summit Therapeutics (SMMT) Announces $100 Million Rights Offering
Jun 22, 2022 04:30PM Summit Therapeutics Announces $100 Million Rights Offering
Jun 3, 2022 08:30AM Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
Jun 1, 2022 08:32AM Summit Therapeutics (SMMT) Appoints Ankur Dhingra as CFO
Jun 1, 2022 08:30AM Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer
May 11, 2022 04:30PM Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
Mar 17, 2022 04:14PM Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
Feb 9, 2022 08:05AM Summit Therapeutics (SMMT) Postpones Planned Rights Offering
Feb 9, 2022 08:00AM Summit Therapeutics Announces Postponement of Its Planned Rights Offering
Jan 25, 2022 07:32AM Summit Therapeutics (SMMT) Announces Rights Offering
Jan 25, 2022 07:30AM Summit Therapeutics Announces Rights Offering
View Older Stories